Nature Reviews Drug Discovery Submission Guide

Source: Clarivate 2026 JCR release; the two median figures come from the NRDD journal metrics page, read on 2026-10-09, which prints no year or article-type scope for them.

Source: NRDD author guidelines, the Nature Reviews Review article format guide, and the journal's editorial policies, read on 2026-10-09.

Use this page when deciding:

• whether the proposed Review has a synthesis argument strong enough for NRDD

• whether the author team has sustained authority in the drug-discovery subfield

• whether topic timing is right for an NRDD presubmission inquiry

• a clear synthesis argument or organizing framework

• author authority with primary-research evidence in the drug-discovery subfield

• topic-timing case (no recent NRDD overlap)

• direct implications for pharma R&D or translational practice

• a synopsis (200-word abstract, main-section outline, key references, and the authors with affiliations) that makes the author authority clear

• Topic recently covered in NRDD or adjacent Nature Reviews journals.

• Author standing in adjacent rather than central drug-discovery research.

• Scope framed as comprehensive survey rather than synthesis.

• Pharma R&D relevance is peripheral.

NRDD is among the highest-impact journals globally and operates a strict commissioning model.

Synthesis-first standard: the journal differentiates from Drug Discovery Today (broader coverage) by demanding an organizing argument, not exhaustive coverage.

The presubmission-inquiry filter: NRDD does not publish a decline rate for unsolicited proposals.

Authority expectation: editors weigh sustained primary-research records heavily.

The strongest NRDD inquiry letters establish:

• the synthesis argument in one sentence

• the author authority with primary-research record

• the topic-timing case

• the pharma R&D relevance

Nature Reviews Drug Discovery asks for a synopsis at the proposal stage:

• 200-word abstract describing the proposed Review's core argument and scope

• Brief description of the main article sections

• List of key references the Review will synthesize

• List of authors and their affiliations, with credentials showing sustained drug-discovery expertise

The author pages list nothing beyond the synopsis. We also suggest a short cover note establishing the synthesis argument and broad pharma R&D relevance (subfield-internal proposals rarely advance), a disclosure of competing interests for all authors (especially pharmaceutical industry consulting, patent holdings, and equity positions), and a check that NRDD has not recently covered the proposed topic.

At the invited full-Review stage, the journal's pages describe these requirements:

• Full manuscript per the Nature Reviews format guidelines

• A data availability statement must be included, and unpublished data, code or materials should be avoided or clearly identified as unpublished; where code is discussed or published datasets are used for further analysis, a code availability or data availability statement should be included

• Written, signed patient consent where the article includes information or photographs that could identify a patient

• Competing interests declared in the article text and in the submission system

• Authorship contributions declared during submission (a statement is published in the final article)

For Nature Reviews Drug Discovery submissions, the most common presubmission-inquiry rejection in our review work is timing collision with recent NRDD coverage. The journal publishes no overlap window or decline timing; as a Manusights rule of thumb, treat a related NRDD Review from the last 12-24 months as a reason to sharpen the angle before proposing.

Nature Reviews Drug Discovery publishes no day-by-day schedule. Its editorial process page describes the stages in order, and its metrics page gives two medians across all submissions: 27 days from submission to first editorial decision and 293 days from submission to acceptance (no year is printed with either figure). Treat both as aggregates, not promises.

Commissioning or proposal

Articles by external authors are invited or commissioned by the in-house editors, and authors may propose Review-type and Comment-type articles as a synopsis through the journal's online submission system, using the link and instructions provided by the editor. The editors may formally commission an article from a proposal.

Submission and initial editorial assessment

The article must not be under consideration at another journal. The editor assesses the organization, structure and accessibility of the article and may recommend changes to the manuscript and display items before formal peer review.

Peer review and revision

Nature Reviews Drug Discovery uses external peer review by several experts in the field, single-blind. The editor returns the referee reports to the corresponding author and gives guidance on how to proceed. A formal rebuttal is required for articles where revisions are requested, and if the editor considers the article adequately revised, it is accepted in principle.

Editing, artwork, copy editing and proofs

In-house editors edit the text and display items, art editors redraw the figures after peer review, all articles are copy edited, and authors review the final text and display items at the proof stage.

• the synthesis argument is clear in one sentence

• the author team has sustained primary-research record in the drug-discovery subfield

• the topic-timing case is strong

• pharma R&D relevance is direct

• Is Nature Reviews Drug Discovery a good journal?

Before inquiring, run your proposal through a Nature Reviews Drug Discovery presubmission readiness check.

Follow the published mechanics, then judge the submission from the other side of the desk. The review tells you whether your paper clears the Nature Reviews Drug Discovery fit check before upload, especially around topic-timing collision with recent NRDD coverage, author standing in adjacent rather than central drug-discovery research, and synthesis-versus-survey framing problems. Paid Manusights reviews include a 60-day money-back guarantee, and we do not train models on submitted manuscripts.

Across Manusights submission reviews for Review proposals targeting NRDD, three patterns generate the most consistent inquiry declines.

In our pre-submission review work, we see many NRDD declines trace to topic-timing collision with recent NRDD coverage. We also often find these cases involve author-authority gaps. A related pattern is that these cases often arise from synthesis-versus-survey framing problems.

Topic-timing collision with recent NRDD coverage

NRDD editors check the journal's recent issues. We observe inquiries proposing topics overlapping NRDD coverage in the prior 3-5 years routinely declined unless a clearly distinct angle is articulated.

Check topic timing collision with recent nrdd coverage before submitting to Nature Reviews Drug Discovery →

Author standing in adjacent rather than central drug-discovery research

NRDD editors weigh sustained primary-research records heavily. We see inquiries from authors with primary research in adjacent pharmaceutical or biological subfields routinely declined unless the drug-discovery connection is direct.

Check author standing in adjacent rather than central drug discovery research before submitting to Nature Reviews Drug Discovery →

Synthesis-versus-survey framing problems

NRDD specifically expects a synthesis argument, not comprehensive coverage. We find that proposals framed as "comprehensive review of topic]" routinely declined; proposals framed around an organizing argument receive better editorial traction. A [NRDD presubmission readiness check can identify whether the inquiry case is strong.

Clarivate 2026 JCR release bibliometric data places NRDD among the highest-impact journals globally.

Check synthesis versus survey framing problems before submitting to Nature Reviews Drug Discovery →

Before the reviewer-invitation stage, read the Nature Reviews Drug Discovery package against the same risks this guide flags in the Manusights section. The package should make the venue choice look deliberate rather than incidental.

• If the abstract still points toward topic-timing collision with recent NRDD coverage, revise the central claim before upload.

• If the evidence package leaves author standing in adjacent rather than central drug-discovery research, strengthen the methods, controls, figures, or supplementary material rather than expecting reviewers to infer it.

• If the cover letter cannot resolve synthesis-versus-survey framing problems, compare the target journal against the adjacent venues named above before submitting.

In pre-inquiry diagnostic work for high-impact commissioning Review journals, we consistently see four signals that distinguish strong proposals from weak ones. First, the proposed topic must align with what NRDD editors are publicly signaling as priority directions through recent editorials, conference participation, and Springer Nature thematic announcements.

Second, the author CV should show 10+ primary-research papers in the exact drug-discovery subfield over the prior decade, not just adjacent-area credentials. Third, the proposal should differentiate sharply from Reviews published in NRDD or adjacent Nature Reviews journals in the prior 5 years; proposals that overlap a recent piece's table of contents are declined on that basis alone.

Fourth, the proposal should be framed in terms of what the synthesis will reorganize or argue, not as comprehensive coverage of recent papers.

For Nature Reviews Drug Discovery-targeted manuscripts, beyond the rubric checks, three pre-inquiry diagnostic patterns recur most often in the proposals we review for NRDD. First, inquiry letters that begin with topic-context paragraphs rather than the synthesis argument lose force in editorial scanning. We recommend the inquiry's opening sentence state the synthesis argument or contrarian thesis; everything else is supporting context.

Second, inquiries where the author authority section uses generic language (we have published in this area) without specifying paper count, journal venues, and specific subfield contributions are flagged at desk for insufficient authority detail. Editors at NRDD expect the authority statement to establish that this team is positioned to write the authoritative Review on this topic.

Third, inquiries that lack engagement with NRDD's recent issues are at risk of being told the proposal doesn't fit the publication conversation. We recommend inquiry authors review NRDD's last 12-18 months of issues before drafting and explicitly cite at least 2-3 Reviews from those issues as positioning context.